The Brain Chemistry Labs, also known as the Institute for Ethnomedicine, under the direction of Dr. Paul Alan Cox, assisted the Government of Samoa, the University of California, Berkeley, and the AIDS Research Alliance in the development of the antiviral drug, Prostratin, which was discovered from a Samoan plant used to treat hepatitis. At the request of the Samoan Government, a Brain Chemistry Labs team identified high-yielding genotypes for cultivation by Samoan villagers.
During ethnobotanical research in Samoa, Dr. Cox was taught by two different traditional healers how to use the bark of the mamala tree (Homalanthus nutans, Euphorbiaceae) to treat patients with hepatitis. The healers, who are typically very modest about their plants, told Dr. Cox that they could treat hepatitis with one or two doses. Collaborating with a team at the National Cancer Institute led by Dr. Gordon Cragg, Dr. John Beutler, and others, Dr. Cox provided samples of the healer potion for analysis with permission of the village chiefs and the Samoan government. The healer potion and the mamala plant from which it was extracted showed extraordinary efficacy against the AIDS virus HIV-1.
Because of the unique ability of Prostratin to prevent death in human cells infected with the AIDS virus, and its ability to expose hidden virus to the action of other drugs, Prostratin was chosen as the major focus of the AIDS Research Alliance. Stanford chemistry Professor Paul Wender and his team made synthetic modifications to the Prostratin molecule, with significant increases to efficacy.
The Brain Chemistry Labs negotiated two major benefit-sharing agreements for Prostratin to benefit the people of Samoa, both of which were considered to be international ground-breaking achievements.
Two agreements
Negotiated by Brain Chemistry Labs to benefit the people of Samoa, and considered international ground-breaking achievements.
- SourceMamala tree bark
- PartnersSamoa, UC Berkeley, ARA
- AntiviralHIV-1
- Led byDr. Paul Alan Cox

